2019 Annual Report ORGANIZATION STRU CTURE We have made several changes which I believe enable us to be more effective in pursuing our goals. First, we reorganized the company into five lines of business and announced several new business leaders to help further drive operating, control, and business performance. C
Financial Performance In 2019, we generated $19.5 billion of net income and diluted earnings per common share (EPS) of $4.05, compared with $22.4 billion of net income and EPS of $4.28 for 2018. Financial performance items for 2019 (compared with 2018) included:
Final 2019 data is expected to be available in April 2020. Investor information Financial statements Strategic report Governance and remuneration GSK Annual Report 2019 35
Revenue recognised in the year that was included in deferred income at 1 January 2019 was £72 million (2018 – £66 million).